In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Galen: European Specialist in US Markets

Executive Summary

In buying rights to market Lilly's Sarafem, Galen figures it can compete with Pfizer and GSK by detailing where they don't--Ob/Gyns. And in growing its valuation, Galen aims to compete with other public European small pharmas by focusing on the US.

Related Content

Galen/Barr: Burying the Hatchet
Galen's Generic Gamble
European Expansion: The Partnering Question


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts